

Partnering for a Purpose – Our Patients.

THE PARTNERSHIP

Clinical studies and commercialization of LONSURF® (trifluridine and tipiracil) tablets for the treatment of metastatic gastric and colorectal cancers in adults in the United States, Europe and other countries around the world.

INSIDE THE DEAL

Co-development and commercialization of LONSURF will be pioneered by Taiho and Servier. Servier has the rights to co-develop and commercialize LONSURF in Europe and other countries outside of the U.S., Canada, Mexico and Asia. Taiho reserves the rights to commercialize and co-develop LONSURF in the U.S., Canada, Mexico and Asia. Taiho also maintains manufacturing and supply rights for LONSURF.

FROM PURPOSE TO PROMISE

- Driving innovation through collaboration and co-creation
- Bringing solutions to patients' lives and accelerating access to therapies
- Working together to discover and develop innovative cancer treatments that address today's patient needs and create a better world for cancer patients and their caretakers



TAIHO PHARMA

